報價延遲最少15分鐘:2026/04/15 09:43 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.615 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.53/-0.63
|
|
企業價值
1.28B
|
| 資產負債 |
|
每股賬面淨值
0.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cellactivation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment. |
